TGFB1 and benign prostatic hyperplasia: In a mouse model of prostatic hyperplasia, administration of doxazosin in dosages well above those used to achieve complete blockade of α1-ADRs in rodents resulted in significant reduction in the wet weight of prostate reconstitutions with retroviral transduction of TGF-β1 [7].